Autologous Stem Cell Transplant in 716 Patients With Multiple Myeloma: Low Treatment-Related Mortality, Feasibility of Outpatient Transplant, and Effect of a Multidisciplinary Quality Initiative

Gertz, Morie A.; Ansell, Stephen M.; Dingli, David; Dispenzieri, Angela; Buadi, Francis K.; Elliott, Michelle A.; Gastineau, Dennis A.; Hayman, Suzanne R.; Hogan, William J.; Inwards, David J.; Johnston, Patrick B.; Kumar, Shaji; Lacy, Martha Q.; Leung, Nelson; Micallef, Ivana N. M.; Porrata, Luis F.; Schafer, Barbara A.; Wolf, Robert C.; Litzow, Mark R.
October 2008
Mayo Clinic Proceedings;Oct2008, Vol. 83 Issue 10, p1131
Academic Journal
We report on the feasibility of outpatient transplant in 716 patients undergoing autologous stem cell transplant for multiple myeloma at Mayo Clinic's site in Rochester, MN, from January 1, 2000, through October 31, 2007. We also report on the development and effect of a multidisciplinary quality initiative implemented by the Mayo Clinic Blood and Marrow Transplant Program involving physicians, nurses, pharmacists, dietitians, and financial specialists for outpatient management of patients undergoing stem cell transplant. This approach uses an electronic ordering system for diagnostic tests and chemotherapy to minimize medical errors. Analysis of hospitalization trends since inception of the program showed that 278 (39%) of the 716 patients treated completed the transplant procedure as outpatients. The median duration of hospitalization for all patients was 4 days; age and serum creatinine levels were predictive of the need for and duration of hospitalization. We also assessed recent treatment-related mortality rates during a 33-month period after implementation of the program (between January 1, 2005, and October 1, 2007). The 100-day survival rate was 99.5% for patients with low-risk myeloma (transplant during first plateau; n=201) and 97.2% for patients with high-risk myeloma (refractory, relapsing or second or greater plateau; n=71). The overall 100-day survival rate was 98.9%. Our experience shows that outpatient transplant is feasible for all patients with multiple myeloma and results in shorter hospital stays and low treatment-related mortality rates.


Related Articles

  • Autologous transplantation for multiple myeloma. Harousseau, J. -L. // Annals of Oncology;Sep2008 Supplement 7, Vol. 19, p128 

    The article presents a study on the use of autologous stem cell transplantation (ASCT) as frontline therapy of multiple myeloma (MM) in younger patients. It states that ASCT is beneficial when all patients are randomized at diagnosis than when randomization is performed after induction...

  • The Real World Effectiveness of Hematopoietic Transplant Among Elderly Individuals With Multiple Myeloma. Winn, Aaron N.; Shah, Gunjan L.; Cohen, Joshua T.; Pei-Jung Lin; Parsons, Susan K. // JNCI: Journal of the National Cancer Institute;8/12/2015, Vol. 107 Issue 8, p1 

    Background: Hematopoietic stem cell transplant (HSCT) is the preferred treatment for young patients with multiple myeloma (MM), but for older adults there is limited evidence on its effectiveness from clinical trials. Methods: We used the Surveillance, Epidemiology, and End Results...

  • Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Olin, R. L.; Vogl, D. T.; Porter, D. L.; Luger, S. M.; Schuster, S. J.; Tsai, D. E.; Siegel, D. L.; Cook, R. J.; Mangan, P. A.; Cunningham, K.; Stadtmauer, E. A. // Bone Marrow Transplantation;Mar2009, Vol. 43 Issue 5, p417 

    Therapeutic options for patients with multiple myeloma whose disease has relapsed after a prior auto-SCT include novel biologic therapies, traditional chemotherapy or a second transplant, with no clear standard of care. Few published studies address the safety and efficacy of a second auto-SCT...

  • New drugs may change the role of transplant in treatment of myeloma. Levitan, Dave // Hem/Onc Today;8/25/2009, Vol. 10 Issue 16, p1 

    This article reports that improving response rates with novel agents have raised a question about the use of stem cell transplant or the urgency to use the procedure as a front-line therapy in patients with multiple myeloma.

  • Reply to 'Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome'. Schroeder, T; Fenk, R; Haas, R; Germing, U; Kobbe, G // Bone Marrow Transplantation;Nov2015, Vol. 50 Issue 11, p1483 

    A response from the author of the article "Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome" in the 2015 issue is presented.

  • Religious Struggle and Religious Comfort in Response to Illness: Health Outcomes among Stem Cell Transplant Patients. Sherman, Allen C.; Simonton, Stephanie; Latif, Umaira; Spohn, Rebecca; Tricot, Guido // Journal of Behavioral Medicine;Aug2005, Vol. 28 Issue 4, p359 

    Growing interest has focused on relationships between health and religious coping among cancer patients. However, little is known about the health correlates of negative or conflicted religious responses. The current study examined general religiousness and two modes of cancer-specific religious...

  • Millennium: pushing for broader use of Velcade.  // PharmaWatch: Biotechnology;Oct2007, Vol. 6 Issue 10, p9 

    The article reports on the plan of Millennium Pharmaceuticals to initiate a Phase II trial that evaluates a Velcade-based for the treatment of multiple myeloma. This randomized trial tends to evaluate a combination of injectable Velcade including Revlimid and dexamethasone. Moreover, an ongoing...

  • Multiple myeloma. Bladé, J.; Cibeira, M. Teresa; Fernández de Larrea, C.; Rosiñol, L. // Annals of Oncology;Oct2010 Supplement 7, Vol. 21 Issue suppl_7, pvii313 

    Multiple myeloma (MM) constitutes 1% of malignant diseases and 15% of haematological malignancies. In virtually all patients MM is preceded by monoclonal gammopathy of undetermined significance (MGUS). The cause of monoclonal gammopathies and the mechanisms of progression are unknown. The...

  • Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma. Lacy, Martha Q.; Gertz, Morie A.; Dispenzieri, Angela; Hayman, Suzanne R.; Geyer, Susan; Kabat, Brian; Zeldenrust, Steven R.; Kumar, Shaji; Greipp, Philip R.; Fonseca, Rafael; Lust, John A.; Russell, Stephen J.; Kyle, Robert A.; Witzig, Thomas E.; Bergsagel, P. Leif; Stewart, A. Keith; Rajkumar, S. Vincent // Mayo Clinic Proceedings;Oct2007, Vol. 82 Issue 10, p1179 

    OBJECTIVE: To determine the long-term effects of a combined regimen of lenalldomide and dexamethasone (Rev-Dex) on time to progression, progression-free survival, and overall survival (OS) in patients with multiple myeloma. PATIENTS AND METHODS: From March 2004 through October 2004, 34 patients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics